Aptevo Therapeutics Inc.
APVONasdaq
$4.74
↑ +5.3%Jul 17 close · end-of-day
Price
1Y↓ -91.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.0M
Enterprise Value
-$9.5M
P/E
0.0
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$26.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-226.1%
ROIC
—
Debt / Equity
—
Net Cash
$14.5M
Return 1Y
-91.2%
Company profile
Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
- CEO
- Marvin L. White
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Washington
- Website
- aptevotherapeutics.com
Management & directors
- Kwon SoyoungSVP, GC, BD & Corp Affairs
- Lamothe Jeffrey G.EVP, COO
- Taylor Daphne LSVP, CFO
- White Marvin LPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
APVO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$6.41↓ -99.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $12.3M | $3.1M | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$27.5M | -$21.4M | -$28.6M | -$28.9M | -$24.6M | -$26.3M |
| Net income | -$17.8M | -$28.5M | $8.0M | -$17.4M | -$24.1M | -$26.0M |
| Diluted EPS | — | -$6.07 | $1.57 | -$2,316.83 | -$31,460.23 | -$87.27 |
| Operating cash flow | -$29.3M | -$21.7M | -$21.0M | -$11.7M | -$23.8M | -$25.6M |
| Free cash flow | -$29.4M | -$22.4M | -$21.1M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -638.1% | -174.1% | -919.7% | — | — | — |
| Net margin | -411.9% | -231.5% | 257.8% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$6.0M | -$5.2M | -$6.4M | -$6.5M | -$6.2M | -$7.6M | -$6.0M | -$6.8M |
| Net income | -$5.9M | -$5.1M | -$6.3M | -$6.4M | -$6.2M | -$7.5M | -$5.8M | -$6.7M |
| Diluted EPS | -$1,236.96 | -$357.86 | -$29,497.20 | -$1,581.81 | -$8.40 | -$2.23 | $1,505.17 | -$6.41 |
| Operating cash flow | -$6.2M | -$5.2M | -$5.8M | -$6.6M | -$7.1M | -$6.7M | -$5.2M | -$8.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-10 | Grant Grady III | Buy | 13,513 | $1.49 | $20,134.37 | filing |
| 2025-07-17 | Harsanyi Zsolt | Option exercise | 1 | — | — | filing |
| 2025-07-17 | Kunz Barbara Lopez | Option exercise | 1 | — | — | filing |
| 2025-07-17 | Abdun-Nabi Daniel | Option exercise | 1 | — | — | filing |
| 2025-07-17 | Grant Grady III | Option exercise | 1 | — | — | filing |
| 2025-07-17 | Niederhuber John | Option exercise | 1 | — | — | filing |
| 2025-07-17 | Taylor Daphne L· SVP, CFO | Option exercise | 3 | — | — | filing |
| 2025-07-17 | Kwon SoYoung· SVP, GC, BD & Corp Affairs | Option exercise | 3 | — | — | filing |
| 2025-07-17 | White Marvin L· President and CEO | Option exercise | 10 | — | — | filing |
| 2025-07-17 | Lamothe Jeffrey G.· EVP, COO | Option exercise | 5 | — | — | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.